Trastuzumab emtansine [Kadcyla®] Product Review

In this review:

This review discusses the use of IV trastuzumab emtansine [Kadcyla®], a HER2-targeted antibodydrug
conjugate, registered for use in New Zealand as a single agent for the treatment of HER2-positive
metastatic breast cancer (please see data sheet for complete indication statement).1 Trastuzumab
emtansine is the first antibody-drug conjugate approved for use in this setting and has proven to
be effective and generally well tolerated.2 Trastuzumab emtansine is not funded by Pharmac.

Please login below to download this issue (PDF)

Subscribe